Ophthalmology Clinical Trials

Current Clinical Trials

Diabetic Macular Edema

  • Boulevard Study – A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema.

Sponsor: F. Hoffmann-La Roche Ltd; Principal Investigator: Paul Yates, MD, PhD

Geographic Atrophy

  • Spectri Study – Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Sponsor: Genentech; Principal Investigator: Yevgeniy Shildkrot, MD

  • Toga Study – Phase II/III, Randomized, Double-Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration.

Sponsor: UVA Dept. of Ophthalmology; Principal Investigator: Paul Yates, MD, PhD

Non-Arteritic Anterior Ischemic Optic Neuropathy

  • QRK Study – A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Sponsor: Quark Pharmaceuticals; Principal Investigator: Steven Newman, MD

Non-Proliferative Diabetic Retinopathy

  • Circle Study – A Phase 2, Randomized, Double-Masked, Sham-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects with Non-Proliferative Diabetic Retinopathy (NPDR)

Sponsor: ThromboGenics; Principal Investigator: Yevgeniy Shildkrot, MD

Open-Angle Glaucoma/Ocular Hypertension

  • Athena Study – A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension

Sponsor: Allergan; Principal Investigator: Bruce Prum, MD

Treatment Naïve Wet Macular Degeneration

  • Avenue Study – Phase II, Multicenter, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.

Sponsor: F. Hoffmann-La Roche Ltd; Principal Investigator: Paul Yates, MD, PhD

  • Cedar Study – Phase III, Multicenter, Randomized, Double-Masked, Parallel-Group, Active-Controlled Study to Assess the Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration

Sponsor: Allergan; Principal Investigator: Yevgeniy Shildkrot, MD

  • Onyx Study – A Randomized, Double-Masked, Active-Controlled Phase II Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration

Sponsor: Regeneron Pharmaceuticals; Principal Investigator: Yevgeniy Shildkrot, MD

For additional information about the trials or to refer a patient, contact the study coordinators:

  • Ashton Leone, MPH at (434) 243-5737 or aml7q@virginia.edu
  • Tamika Mercer at (434) 243-2852 or tmm2v@virginia.edu